VistaGen Therapeutics (NASDAQ: VTGN) CEO, Shawn Singh, sits down with WSM’s Jason Lin at Nasdaq to discuss the Company’s pipeline of new generation medicines for CNS diseases and disorders including AV-101 and PH10 for the treatment of major depressive disorder and PH94B for the on-demand, as-needed treatment of social anxiety disorder.
VistaGen CEO Shawn Singh Highlights Company Pipeline – WSM Interview with Jason Lin
